Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for ADHERA THERAPEUTICS, INC. (ATRX : OTC)
 
 • Company Description   
Adhera Therapeutics Inc. is a bio-technology company. It researches and develops therapies for the treatment of inflammatory diseases, hyper-tension and cancer. The company's product pipeline consists of PRESTALIA(R) and DyrctAxess which are in clinical stage. Adhera Therapeutics Inc., formerly known as Marina Biotech Inc., is based in Durham, United States.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.06 Daily Weekly Monthly
20 Day Moving Average: 42,144 shares
Shares Outstanding: 17.49 (millions)
Market Capitalization: $1.11 (millions)
Beta: -0.04
52 Week High: $0.48
52 Week Low: $0.04
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.46% -8.17%
12 Week -18.77% -10.71%
Year To Date -14.05% 5.01%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
8000 INNOVATION PARKWAY
-
BATON ROUGE,LA 70820
USA
ph: 919-518-3748
fax: 206-830-9424
info@adherathera.com None
 
 • General Corporate Information   
Officers
Andrew Kucharchuk - Chief Executive Officer and Chairman
Charles L. Rice - Director
Trond K Waerness - Director
Zahed Subhan - Director
Erik Emerson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00687E109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/22/22
Share - Related Items
Shares Outstanding: 17.49
Most Recent Split Date: 8.00 (0.10:1)
Beta: -0.04
Market Capitalization: $1.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/22/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 75.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -4,291.23
12/31/21 - -6,513.85
09/30/21 - -10,592.82
Current Ratio
03/31/22 - 0.01
12/31/21 - 0.01
09/30/21 - 0.01
Quick Ratio
03/31/22 - -
12/31/21 - 0.01
09/30/21 - 0.01
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -1.46
12/31/21 - -1.48
09/30/21 - -1.35
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©